Daily Pre-Market News11/13/2026 8:16:14 AM ET

US-Iran Tensions, Nvidia Chaos, Oil Volatility: Market on Edge!

In today's volatile market landscape, geopolitical tensions and sector-specific dynamics are shaping investor sentiment and market movements. The escalation of US-Iran tensions has injected a layer of uncertainty, prompting investors to seek refuge in traditionally safer assets. This geopolitical backdrop is influencing the broader market, with the S&P 500, Nasdaq, and Dow Jones Industrial Average experiencing fluctuations as investors navigate the complex interplay of risk and opportunity. In the semiconductor sector, Nvidia's recent turmoil has sent shockwaves through the industry. The departure of CEO Jensen Huang has raised questions about the company's future leadership and strategic direction. Despite initial double-digit losses, Nvidia's stock has shown resilience, buoyed by retail investors who have capitalized on the dip. This decoupling from the broader market underscores the unique challenges and opportunities within the semiconductor space, particularly as Nvidia navigates its next phase without its visionary leader. The airline sector is also undergoing significant shifts, with companies adjusting to fluctuating demand and operational challenges. Investors are closely monitoring these developments, as the sector's recovery remains contingent on broader economic conditions and consumer confidence. Energy markets are another focal point, with oil prices experiencing volatility amid geopolitical tensions and supply chain considerations. The potential for a supply surplus, as indicated by the International Energy Agency, adds another layer of complexity for investors assessing the sector's outlook. Corporate developments further complicate the market narrative. BioNTech's potential to emulate Moderna's success has captured investor attention, with the stock poised for significant gains. Meanwhile, Nvidia's scandal, while damaging in the short term, may present hidden upside potential for the AI trade if the company successfully navigates its leadership transition. Inflationary pressures continue to loom large, with the Producer Price Index set to provide further insights into input costs. This data will be crucial for assessing the broader economic landscape and its implications for corporate earnings and market performance. As the market grapples with these multifaceted challenges, investors are urged to remain vigilant, balancing macroeconomic trends with micro-level corporate developments. The interplay between geopolitical volatility, sector-specific rotations, and corporate outcomes will continue to define the market's trajectory in the coming days.

Companies Reporting Earnings Today

SymbolPriceChangeMarketCap
MUFG21.750000-0.87%246597054866
MFG10.120000-0.39%123163804054
BPYPN13.290000-1.99%92955115502
ATH-PA22.4000000.18%71662393040
WF69.840000-0.40%17080645951
BPYPO14.6300000.00%6535242652
BPYPP15.072700-0.31%6323498320
CSAN2.750000-1.61%5388558436
AVAL3.950000-6.18%4689336316
ATH-PB15.520000-2.76%3162976000
ATH-PD13.490000-2.46%2749262000
PPTA17.820000-5.91%2229207156
SEAL-PB25.0700000.56%2181240420
AHL-PD16.8200000.12%2176395827
ALM7.630000-6.50%2164951460
DRVN11.530000-3.60%1902217278
FBRX76.9900000.00%1634427408
AHL-PE16.8650000.09%1548906965
INBX87.745000-3.14%1291401077
GHRS18.490000-3.95%1269195887
GDRX3.510000-3.84%1197420287
SCCD24.9050000.02%1167426532
SCCF24.150000-0.41%1151740065
SCCG24.042500-0.51%1146613272
SCCE24.381200-0.38%1142873309
FGNXP25.6002002.81%1015203682
AZUL5.0000001.01%970561955
USAS2.790000-5.74%943459743
ORIC8.500000-5.56%881047576
PMI7.850000-2.36%806163090
SCZM7.050000-4.21%655581502
CADL8.390000-9.00%641990760
SGML5.010000-2.91%563965680
NFEGP225.0000000.78%552360600
SBC5.3400001.91%549202713
CEPF10.330000-0.19%474147000
GRVY67.410000-1.32%468425349
GLOP-PB25.8900000.15%415187600
BOC13.710000-0.22%413035192
GLOP-PC25.4900000.67%408772959
GLOP-PA25.1500000.20%403320540
CDROW0.016000-15.34%388313074
WSBF20.1400000.30%362057344
TLNC10.2800000.15%349304089
CDZIP19.5000000.51%331711224
BNTC9.090000-4.01%317143737
MLP15.050000-0.40%298880960
ORBS0.673400-8.57%282431032
CDZI3.320000-1.78%282265935
LRMR2.700000-1.10%280484100
XSLL10.040000-0.10%277907612
ELA10.390000-1.52%269760516
SSII1.320000-12.58%264630960
CEPV10.210000-0.20%260763400
GLSI15.280000-5.03%224283018
DGXX2.210000-3.07%224086683
CDR-PC16.250000-2.93%222920246
CEPO10.8100000.00%221605000
EIC8.880000-0.11%208089960
GALT3.140000-4.56%206790660
KGEI5.5600002.39%199806912
ELDN2.365000-11.42%192182624
RMIX8.120000-3.22%190215052
MDV18.050000-0.88%186342244
IMPPP25.9173001.04%183851780
AIRJW0.3537004.21%173833324
GMTL4.300000-3.37%167534863
IMPP4.430000-0.89%166529977
NXDT3.060000-2.24%162504360
FUFU0.9089005.62%151471450
BEBE10.0900000.10%151350000
GDEV8.339900-12.58%151117103
ALXO1.080000-3.57%149339157
USDE6.130000-6.70%147303900
FUFUW0.080800-8.91%146831750
SRG-PA20.3000000.00%146116781
OWLT4.6200000.43%135004148
MENS1.680000-3.45%127726470
CEPS10.170000-0.20%120006000
AREC1.030000-4.19%110180410
IMUX7.790000-4.06%106290390
JFB4.9450000.00%100039343
EP2.400000-2.44%99845520
SIDU0.955800-13.11%96655581
HURA1.450000-4.61%92403570
RDZN1.040000-7.96%88571666
SRG1.5400000.65%86739895
NDLS13.750000-3.17%82041575
FSI6.410000-1.23%81884532
MIST0.655200-1.06%81571076
PZG0.945500-3.41%81516643
NMRA0.433000-8.46%81358925
RTB5.530000-0.90%80156244
RDI1.8700002.19%65402827
DGNX1.2700005.83%63665265
EVTL0.377100-9.35%63594494
FGNX7.8000001.30%61732835
PVL1.8100002.26%59730000
SPAI2.810000-7.57%58953648
ZSTK2.600000-2.99%56672782
PDSB0.980000-3.92%54699340
XXI5.000000-4.94%51500000
RDIB12.200000-0.49%51182111
ATNM1.5900000.00%49991883
RNTX0.560000-7.59%48309520
DVLT0.056400-7.39%48253697
CNVS1.8100000.56%48199757
HOWL0.980000-0.90%47627118
DWSN1.530000-3.16%47515068
ICG1.440000-1.03%44057372
VHC9.650000-3.40%40491477
QXL3.0200000.00%40275904
SCWO2.210000-3.07%38950698
SEV1.520000-2.56%37434093
PHUN1.740000-1.69%35976762
ROLR3.2600001.88%35955560
OSTX0.750100-14.00%35108603
SBCWW0.340000-5.56%34967963
SACH0.700100-11.40%33573038
SACH-PA18.000000-4.76%33573024
ONMD5.350000-0.37%31162926
TOON0.495000-1.73%30791030
RPID0.671000-10.19%30637860
BNAI4.440000-5.53%30063777
HHS4.0300002.03%30040587
PUSA1.3900004.51%30030509
FGIWW0.05198172.69%27327179
SAFX0.070000-2.64%25442445
PSHG2.020000-1.70%25112959
BZAI0.173000-8.47%25087320
BYSI0.601000-6.65%24713012
AAME1.190000-4.80%24272701
FIEE2.800000-5.72%23880074
TVGN5.720000-4.67%23819253
UAVS0.363700-5.87%22878803
BRAG0.6826002.03%21203877
ENLV1.245000-1.19%20955859
COSM0.207600-12.07%20891571
BESS2.900000-17.61%20582953
SMXT4.260000-3.84%20201631
COCP0.990000-2.94%19070568
NYC5.710000-4.39%18064327
LOCL0.760800-0.48%17788645
CIRC0.1961003.87%17641156
CNTY0.5974008.62%16809457
RVP0.5550000.09%16615123
BEEM0.6801001.02%16286528
AEI0.400100-17.47%15562222
TVRD1.155000-13.81%15406430
LONA3.790000-2.32%14947862
ALLR0.913800-2.30%14539220
IDAI2.510000-4.56%14269167
BFRI0.925900-1.24%13751799
MDRR10.5000004.69%13011201
CMCT4.99000015.24%12758632
OPTH2.180000-9.17%12482390
PTN6.570000-4.23%11700769
BBGI5.630000-5.70%11556983
LSTA1.2800006.67%11534003
PAVM1.339000-16.57%10706534
BFRG0.553000-4.67%10253532
BENF0.652900-4.08%10093072
GDTC0.8440000.48%9986913
ATER0.869000-6.05%9428137
LFWD5.720000-0.69%9214926
ZEO0.25470015.51%9016372
CURX5.6700000.18%8891926
PBK0.141500-0.21%8755796
VTGN0.178800-4.79%7934590
AEON0.158700-7.41%7916399
TPST0.383000-3.53%7658222
FTFT4.04000014.77%7547427
CABR0.804300-6.57%7312298
IQST0.735000-6.96%7078050
BIRD1.110000-11.90%6965058
NDRA4.640000-2.70%6959258
LTRN0.460600-4.24%6879326
ENVB1.5200002.01%6803344
SLE3.970000-7.03%6729626
SUNE1.950000-2.99%6498695
FBLG0.967800-2.81%6443799
MSN0.2975002.92%6260189
SKYQ1.2500005.93%5993308
GAUZ5.180000-4.35%5921439
BZAIW0.012700-16.45%5670563
JAGX0.399900-17.10%5337059
DSS0.5200008.81%5222100
PCSA1.840000-1.60%5148762
BTOC1.810000-1.09%5140809
PLAG0.360700-3.71%5133740
MITQ0.5047000.94%5022885
FTHM0.142600-2.19%4877952
GTBP3.840000-2.78%4846679
TWAV1.2400001.64%4807752
CHAI0.1849007.56%4782780
PULM1.299900-0.77%4747605
OLB0.179900-2.33%4321254
SBFMW0.0255000.00%4182323
MGRX0.185000-7.18%4111518
GRI1.820000-0.55%3978729
BKYI2.5800004.03%3705757
HYFM0.7499000.36%3614008
KALA0.161000-5.85%3113708
JTAI0.860100-6.49%3059824
RENX1.1400000.88%3016678
SQFTP6.3200001.94%3007031
NXXT1.7000000.00%2862800
BNAIW0.054100-16.77%2778441
AIDX0.203800-9.38%2724236
OBAI1.6600000.00%2721210
TOPP0.1080000.00%2667600
CNET0.700000-26.00%2567900
ARAI2.060000-27.26%2367636
ATXG2.290000-15.19%2361986
AMZE0.112000-11.60%2332307
XPON2.410000-5.90%2297190
BGLC0.9065005.54%2191295
NCRA1.400000-3.45%2184456
PPCB1.9200004.35%1983575
CJMB0.37710022.00%1801756
KAPA0.483100-5.26%1635479
APVO0.660100-13.14%1443544
ELAB1.5900000.63%1287231
BOXL1.9100003.80%1274079
SQFT0.850000-0.35%1219266
SQFTW0.008600-9.47%1150684
BENFW0.00720018.03%1147930
VJET0.525000-3.85%1103543
VBIO0.5086001.15%1096356
ONCO3.030000-19.41%1086028
ASBP8.400000-4.55%969125
CHGA0.93910010.47%682129
GNLN0.966000-6.21%670930
PWCM0.480500-0.74%449104
CDR-PB17.1501000.27%421910
MTNB0.918400-1.25%392229
IPDN0.809400-16.12%389869
ICON0.9299004.48%369896
SDST0.0082002.50%332732
NVVE0.590100-1.65%309597
HCWB0.800600-6.91%278321
PPBT1.5600004.70%215411
DBGI0.20400039.63%190436
CTNT1.600000-3.61%31530
PARAW0.006500116.67%21324
MSPR0.0001000.00%1377

6-K/8-K Form Update

BNTC

Benitec Biopharma Inc. reported its first fiscal quarter 2027 financial results, revealing total expenses of $14.5 million, up from $9.8 million in the same period in 2025, with research and development expenses rising to $8.6 million from $3.4 million. The company announced a change in its fiscal year-end from June 30 to December 31, effective from January 1, 2027, to enhance comparability of results. Benitec also presented positive interim clinical results from the BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy, showing a 100% responder rate with no serious adverse events, and remains on track to begin the pivotal trial in mid-2027. As of September 30, 2026, the company held approximately $176 million in cash and cash equivalents.

EDBLW

Edible Garden AG Incorporated announced a reverse stock split of its common stock at a 1-for-5 ratio, effective November 17, 2026. The modification, disclosed in an 8-K report, will consolidate every five shares into one, with the new CUSIP identifier 28059P709, while warrants remain under the symbol EDBLW. The total number of authorized shares remains unchanged, and no fractional shares will be issued.

MIST

Milestone Pharmaceuticals Inc. announced third-quarter 2026 financial results, highlighting cost-efficiency measures to extend cash runway through the AFib-RVR Phase 3 data readout in 2H 2028 while maintaining sales force and core commercial activities for CARDAMYST (etripamil) nasal spray. The company reported net product revenue of $1.0 million for CARDAMYST in Q3 2026, a 73% increase from Q2 2026, with approximately 3,400 prescriptions written by around 1,600 unique prescribers. Milestone expects cash and equivalents of $145.4 million as of September 30, 2026, providing an operating runway into late 2028, beyond prior guidance.

RGS

Regis Corporation announced the departure of Executive Vice President and Chief Financial Officer Kersten Zupfer, effective upon the appointment of a new CFO. Ms. Zupfer will remain in a non-officer capacity to assist with the transition before her employment ends, during which she will receive severance benefits. The company is currently initiating a search for a successor CFO.

SBCWW

SBC Medical Group Holdings Incorporated reported a 35% year-over-year revenue increase to $59 million for the third quarter of 2026, with net income up 22% to $16 million and adjusted EBITDA soaring 66% to $28 million. The company's operating margin improved to 45%, and net cash from operations reached $50 million for the nine months ended September 30, 2026. Growth was driven by higher management services revenue and the consolidation of Waqoo, with the clinic network expanding by 36 locations to 293, and patient visits rising 9% to 7.06 million.

VRT

Vertiv Holdings Co increased its regular annual cash dividend from $0.25 to $0.40 per share, effective with the fourth-quarter dividend. The company's Board of Directors approved this 60% increase, citing strong financial performance and cash flow as enabling factors. This adjustment reflects Vertiv's commitment to returning value to shareholders.

MZHOF

Mizuho Financial Group, Inc. reported a 15.1% increase in ordinary income to ¥4,993 billion for the second quarter of fiscal 2026, with ordinary profits rising 47.3% to ¥1,252 billion and profit attributable to owners of the parent up 29.9% to ¥896 billion. The company's total assets stood at ¥320,857 billion, with total net assets at ¥11,269 billion, and an own capital ratio of 3.4%. Mizuho announced a total fiscal 2026 dividend estimate of ¥200.00 per share and revised its earnings estimate to ¥1,600 billion, a 14.2% increase.

USAS

Americas Gold and Silver Corporation reported record quarterly silver production of 800,458 ounces, a 5% increase from Q3-2025, driven by strong performance at Cosalá Operations and recovery at the Galena complex. The company achieved a 68% increase in consolidated net revenue to $51.4 million for Q3-2026, with year-to-date revenues rising 104% to $165.5 million. Operational highlights include a 28% year-over-year increase in silver production at Cosalá and promising new drill results at the Galena Complex, supporting future mine plans.

SMFNF

Sumitomo Mitsui Financial Group, Inc. reported a 11.4% increase in ordinary income to ¥5,800,081 million for the six months ended September 30, 2026, compared to the previous year. The company's total assets decreased to ¥326,234,790 million as of September 30, 2026, from ¥328,411,534 million as of March 31, 2026, with a net assets ratio of 4.9%. Dividend payments for the first quarter of fiscal year 2027 were announced at ¥78.00 per share, with an earnings forecast of ¥1,900,000 million profit attributable to owners of parent, translating to ¥250.84 per share before a two-for-one stock split.

TSMWF

Taiwan Semiconductor Manufacturing Company Limited reported a 41% increase in total revenue, reaching $3.9 trillion for the nine months ended September 30, 2026, up from $2.8 trillion in 2025. Gross profit surged by 59% to $2.6 trillion, while net income rose by 69% to $2.0 trillion. Operating expenses, notably research and development, grew by 27%, and cash and cash equivalents increased by 46% to $3.6 trillion. Total liabilities rose by 30% to $3.0 trillion, driven by a significant increase in bonds payable.

VINP

Vinci Compass Investments Ltd. reported its third quarter 2026 earnings, showcasing a record Fee Related Earnings (FRE) of R$106.8 million (R$1.61 per share) and a FRE Margin of 34.3%. The company declared a quarterly dividend of US$0.17 per share and completed the Navi acquisition, followed by the AustralRe acquisition, which is expected to redefine its role in the region. With assets under management and advisory reaching R$363 billion, Vinci Compass is positioned for its next growth phase.

PAYP

PayPal Corporation reported its second quarter 2026 financial results, showing a revenue increase to ¥146.83 billion from ¥76.87 billion in the same period of 2025, and a net profit of ¥38.19 billion, up from a loss of ¥2.45 billion in Q2 2025. The company's total assets grew to ¥5.73 trillion from ¥5.27 trillion, while total liabilities remained stable at ¥5.27 trillion, with notable growth in accounts payable and borrowings. Adjusted earnings per share figures reflect the company's financial health and operational performance, influenced by a share split effective November 15, 2025.

CLLS

Cellectis reported third-quarter 2026 financial results, showing $149 million in cash, cash equivalents, and fixed-term deposits as of September 30, 2026. The company announced progress in its in vivo gene editing pipeline, with.HEAL-101 achieving up to 70% APOC3 editing in a humanized liver model and reducing triglycerides by 76%, and.HEAL-201 achieving over 90% PCSK9 reduction in a liver-humanized mouse model. Cellectis plans to initiate a Phase 1 Investigator-initiated Trial (IIT) in China for.HEAL-101 in the second half of 2027 and a Phase 1 IIT in China for.HEAL-201 by the first half of 2028, while executing a strategic transformation to become an in vivo gene editing company, leading to a planned reduction of up to 70% of its global headcount over 2026 and 2027.

Pre-Market Options Data